Navigation Links
Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
Date:10/30/2007

KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Leading researchers will present 68 data presentations involving Schering-Plough's hepatitis products, including PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy, a current standard of care in the treatment of chronic hepatitis C, at the 58th American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Nov. 2-6.

Among these are several studies discussing the predictability of response with PEGINTRON and REBETOL and assessing how results at important treatment milestones early in the course of therapy can help physicians and patients make informed treatment decisions.

Researchers will present the final results from the POWeR (Peginterferon alfa-2b Prospective Optimal Weight-based Dosing Response) program, a large observational study involving nearly 2,000 patients conducted at academic and community clinics in Canada between 2002 and 2006. In the study, PEGINTRON and REBETOL combination therapy achieved consistent sustained virologic response (SVR) rates across patient weights and consistently low relapse rates in a "real-life" treatment setting.

Investigators also will present new data on the investigational use of low-dose PEGINTRON as maintenance therapy in chronic hepatitis C nonresponder patients with fibrosis or cirrhosis. The goal of maintenance therapy in this very hard-to-treat patient population is to prevent or delay the progression of liver disease.

Hepatitis C is the most common blood-borne infection in America and the most common form of liver disease, affecting nearly 5 million people in the United States and 200 million people worldwide.

For program information, please visit the American Association of Liver Disease Web site at http://www.aasld.org.

Key PEGINTRON Presentations:

Predictability of Response

Predictability of Response:
'/>"/>

SOURCE Schering-Plough
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
4. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
5. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
6. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
7. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
8. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
9. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market 2014-2018" report to their offering. ... needle is a hollow needle commonly used with a ... to extract fluids from it. A hypodermic needle is ... substances that cannot be ingested. Hypodermic needles are broadly ...
(Date:7/11/2014)... MELBOURNE, Australia , July 11, 2014  Australian ... today announced that it has raised A$19.3 million via ... Europe , the U.S., ... and A$3 million from a share purchase plan (SPP) ... A$16.3 million will be made in two tranches. ...
(Date:7/11/2014)... New York , July 11, 2014 ... by Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic ... Size, Share, Growth, Trends and Forecast, 2013-2019" the global ... in 2012 and is expected to grow at a ... an estimated value of USD 36.9 billion in 2019. ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
... A. Grant, MD,Retina Macular Care, presented the ... that was designed to evaluate the adjuvant,use ... Lucentis(R),(ranibizumab) treatment of choroidal neovascularization secondary to,age-related ... presentation at,the 2008 Annual Meeting of the ...
... C Therapies Provides ... Clinical Practice, MILAN, Italy, April 26 Final ... study comparing the,leading therapies for chronic hepatitis C, were ... Association for the Study of the Liver,(EASL), providing important ...
Cached Medicine Technology:Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 3Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 2Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 3Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 5Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 6Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 7Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 8Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 10
(Date:7/11/2014)... Biostimulants are widely applied in turf ... ornamentals. These also help turf and ornamentals in absorption ... Turf, ornamentals, and flowers appear healthy and strong as ... increased from the last few years. The most dominating ... Europe, with around 40% share in 2013, and is ...
(Date:7/11/2014)... and overweight firefighters are not receiving weight management ... new research from The University of Texas Health ... state that health care professionals (HCPs) should advise ... weight. Firefighters have high rates of obesity, and ... deaths in firefighters. This study assessed the association ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... from the worldwide scourge of dengue fever was somewhat successful ... only prevented dengue fever in 56 percent of the 10,000 ... protected more than 88 percent of them from severe disease. ... and sometimes death. "This vaccine has already proven to ...
(Date:7/11/2014)... VA (PRWEB) July 11, 2014 Riverside Health ... Care (CBCC) in Virginia in late 2012 and now, ... ChooseHome – to residents throughout the Williamsburg and Newport News ... programs provide services and benefits to independent older adults who ... access to a safety net of continuing care services as ...
(Date:7/11/2014)... 11, 2014 Pigments are insoluble colorants, ... three functions namely protective coating, opacity, and coloring. These ... that impart color to substances such as paper, paints, ... pigments, which upon application impart color to the substance. ... carbon black, and hematite. , The coloring action of ...
Breaking Medicine News(10 mins):Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3
... Acquisition Will Extend Product Offering to Healthcare Customers, ... CLAI), a leading provider of electronic transaction services ... entered into an agreement,to acquire substantially all the ... The agreement is subject to due diligence and ...
... DES MOINES, Iowa, Dec. 13 If Congress passes,legislation ... authority,to regulate tobacco products, the new law would save ... keeping 25,700 kids from,becoming new smokers, according to a ... Senator Tom Harkin is a cosponsor of the,legislation. Senator ...
... part of St. Josephs Health Care, London and a ... at The University of Western Ontario. His team ... thousand Canadian peacekeeping veterans with service-related disabilities. The ... served with the Canadian Forces from 1990 to 1999. ...
... publishers, will begin publishing La Chirurgia degli Organi de ... is the official publication of the Istituti Ortopedici Rizzoli, ... It is published three times a year entirely ... Musculoskeletal Surgery, founded in 1917 at the Istituti ...
... COLUMBIA, Mo. Researchers from the University of Missouri ... vaccines directed against the virus that causes AIDS and ... published in the Dec. 14 edition of The Journal ... than a decade, Gary Clark, associate professor of Obstetrics, ...
... 13, 2007 Schizophrenia is one of the most debilitating ... the most difficult to treat. Although numerous antipsychotic treatments ... patients experience only a partial relief of their symptoms and ... new study scheduled for publication in the December 15th issue ...
Cached Medicine News:Health News:Claimsnet to Acquire Acceptius 2Health News:New Report: Tobacco Regulation Would Save Iowa $449 Million in Health Care Costs by Preventing 25,700 Kids from Smoking 2Health News:New Report: Tobacco Regulation Would Save Iowa $449 Million in Health Care Costs by Preventing 25,700 Kids from Smoking 3Health News:New study suggests why vaccines directed against cancer, HIV don't work 2Health News:Effective new treatment for schizophrenia 2